OR WAIT null SECS
October 26, 2026
Video
In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.
October 22, 2026
Article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
May 28, 2026
Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.
May 20, 2026
This interview at ATS highlights key takeaways regarding new phase 3 data on AD109 for obstructive sleep apnea (OSA).
May 19, 2026
This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).
This potential new treatment option shows potential for patients living with obstructive sleep apnea.
April 13, 2026
Schneider discusses her analysis of the FINEARTS-HF trial, noting the apparent efficacy of finerenone regardless of sleep apnea presence.
December 31, 2025
From FDA decisions to late-phase trial readouts and updated practice guidelines, 2025 delivered clinically actionable insights across sleep conditions.
October 22, 2025
Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.
October 20, 2025
CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.